58diagnostics is a medtech company developing the first portable breathalyzer to detect and monitor heart failure.
Heart failure is a chronic condition that worsens over time and is characterized by the heart's inability to pump enough blood to the rest of the body. It is as prevalent as all cancers combined and as deadly as leukemia. Diagnosis is often delayed because symptoms are difficult to interpret. The ability to tightly monitor changes in severity after diagnosis is critical to improving outcomes as well, yet there is a lack of solutions. Risk factors include age, COPD, diabetes, high blood pressure, plaque buildup in arteries, and valve disease, among others.
While heart failure is a growing concern, the road to better outcomes can be achieved with earlier detection and regular monitoring. We are passionate about transforming this potential into reality.
58diagnostics is headquartered in New York City.
For more information, please visit our website at www.58diagnostics.com. To contact us, email our Director of Investor Relations, Geoff McGrane, at geoffrey@58diagnostics.com.